The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | Treating newly diagnosed myeloma in the UK: options available and important factors to consider
Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, comments on the treatment options available in the UK for newly diagnosed multiple myeloma (MM), and highlights the importance of determining whether a patient is transplant eligible or ineligible when making treatment decisions. As a result of the recent approval of daratumumab plus lenalidomide and dexamethasone (Dara-Rd) based on data from the MAIA trial (NCT02252172), Prof. Jackson emphasizes that there is less of a need to take patients to transplant if it is not an appropriate therapeutic approach for them. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
There are two main treatments and the key factor is to decide whether your patient is transplant eligible or ineligible. So obviously at the moment we have Dara-VTd, four lines of therapy, stem cell transplant, two lines of consolidation and then Revlimid maintenance. But we’ve recently had Dara-Rd approved in the MAIA study, it is approved for the elderly, which shows fantastic outcomes...
There are two main treatments and the key factor is to decide whether your patient is transplant eligible or ineligible. So obviously at the moment we have Dara-VTd, four lines of therapy, stem cell transplant, two lines of consolidation and then Revlimid maintenance. But we’ve recently had Dara-Rd approved in the MAIA study, it is approved for the elderly, which shows fantastic outcomes. So I think our decision making is really around which group do our patient or the patient in front of us fall into. Is this a transplant eligible patient or is that a transplant ineligible patient? And I think before the approval of Dara-Rd, we were trying to push a lot more patients into transplant, perhaps going up to late 60s, early 70s in terms of pushing those patients through. I think with the advent of the MAIA data and Dara-Rd, I think the outcomes are really quite impressive and we don’t need to push the envelope now on stem cell transplantation. So I think our major decision making is around stem cell transplant eligible or ineligible. And also, are there any trials available? Because as we’ve heard this morning, all of the progress we make is through clinical trials.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Johnson & Johnson, Amgen, Sanofi, Bristol Myers Squibb, Takeda, Pfizer, Menarini: Honoraria for advisory boards/speaking; Onyx, Bristol Myers Squibb, Takeda: Research Funding.
